Natalie Joseph-Williams1, Robert Newcombe1, Mary Politi2, Marie-Anne Durand3, Stephanie Sivell4, Dawn Stacey5, Annette O'Connor6, Robert J Volk7, Adrian Edwards1, Carol Bennett5, Michael Pignone8, Richard Thomson1,9, Glyn Elwyn1,10. 1. Institute of Primary Care and Public Health, Cardiff University, Cardiff, UK (NJ-W, RN, AE, GE) 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO (MP) 3. Department of Psychology, University of Hertfordshire, Hatfield, UK (M-AD) 4. Marie Curie Palliative Care Research Centre, Wales Cancer Trials Unit, Cardiff University, Cardiff, UK (SS) 5. Faculty of Health Sciences, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada (DS,CB) 6. Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada (AO) 7. Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (RJV) 8. Division of General Internal Medicine, University of North Carolina Department of Medicine, Chapel Hill, NC (MP) 9. Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK (RT) 10. Dartmouth Center for Health Care Delivery Science, Dartmouth College, Hanover, NH (GE).
Abstract
OBJECTIVE: The IPDAS Collaboration has developed a checklist and an instrument (IPDASi v3.0) to assess the quality of patient decision aids (PDAs) in terms of their development process and shared decision-making design components. Certification of PDAs is of growing interest in the US and elsewhere. We report a modified Delphi consensus process to agree on IPDASi (v3.0) items that should be considered as minimum standards for PDA certification, for inclusion in the refined IPDASi (v4.0). METHODS: A 2-stage Delphi voting process considered the inclusion of IPDASi (v3.0) items as minimum standards. Item scores and qualitative comments were analyzed, followed by expert group discussion. RESULTS: One hundred and one people voted in round 1; 87 in round 2. Forty-seven items were reduced to 44 items across 3 new categories: 1) qualifying criteria, which are required in order for an intervention to be considered a decision aid (6 items); 2) certification criteria, without which a decision aid is judged to have a high risk of harmful bias (10 items); and 3) quality criteria, believed to strengthen a decision aid but whose omission does not present a high risk of harmful bias (28 items). CONCLUSIONS: This study provides preliminary certification criteria for PDAs. Scoring and rating processes need to be tested and finalized. However, the process of appraising the quality of the clinical evidence reported by the PDA should be used to complement these criteria; the proposed standards are designed to rate the quality of the development process and shared decision-making design elements, not the quality of the PDA's clinical content.
OBJECTIVE: The IPDAS Collaboration has developed a checklist and an instrument (IPDASi v3.0) to assess the quality of patient decision aids (PDAs) in terms of their development process and shared decision-making design components. Certification of PDAs is of growing interest in the US and elsewhere. We report a modified Delphi consensus process to agree on IPDASi (v3.0) items that should be considered as minimum standards for PDA certification, for inclusion in the refined IPDASi (v4.0). METHODS: A 2-stage Delphi voting process considered the inclusion of IPDASi (v3.0) items as minimum standards. Item scores and qualitative comments were analyzed, followed by expert group discussion. RESULTS: One hundred and one people voted in round 1; 87 in round 2. Forty-seven items were reduced to 44 items across 3 new categories: 1) qualifying criteria, which are required in order for an intervention to be considered a decision aid (6 items); 2) certification criteria, without which a decision aid is judged to have a high risk of harmful bias (10 items); and 3) quality criteria, believed to strengthen a decision aid but whose omission does not present a high risk of harmful bias (28 items). CONCLUSIONS: This study provides preliminary certification criteria for PDAs. Scoring and rating processes need to be tested and finalized. However, the process of appraising the quality of the clinical evidence reported by the PDA should be used to complement these criteria; the proposed standards are designed to rate the quality of the development process and shared decision-making design elements, not the quality of the PDA's clinical content.
Authors: Elizabeth M Schoenfeld; Connor Houghton; Pooja M Patel; Leanora W Merwin; Kye P Poronsky; Anna L Caroll; Carol Sánchez Santana; Maggie Breslin; Charles D Scales; Peter K Lindenauer; Kathleen M Mazor; Erik P Hess Journal: Acad Emerg Med Date: 2020-02-16 Impact factor: 3.451
Authors: Carolien Wentink; Marloes J Huijbers; Peter Lbj Lucassen; Annoek van der Gouw; Cornelis Kramers; Jan Spijker; Anne Em Speckens Journal: Br J Gen Pract Date: 2019-10-31 Impact factor: 5.386